Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an Open-Label Extension Trial (P5.5-005)

Assess the long-term safety and efficacy of add-on CBD treatment in patients with Dravet syndrome (DS) in the second interim analysis of the open-label extension (OLE) of two Phase 3, randomized controlled trials, GWPCARE1 and GWPCARE2.